← Full program

From Network to Hardware: Next-Gen BCI for Neural Recovery

Part of Plenary I: Rewiring the Future: Precision Neuromodulation Across Brain Networks

Details

Date
Friday, January 22, 2027
Time
9:11 AM – 9:25 AM
Session type
Plenary
Schedule
See this day

About

Advances in computational neuroscience, connectomics, brain-computer interfaces, and systems-level understanding of brain function are rapidly changing the landscape of neuromodulation beyond symptom control to precision-guided interventions with the purpose to identify neural biomarkers, map functional brain networks, restore neurological function, and explore the fundamental mechanisms underlying consciousness itself. This plenary session brings together internationally recognized leaders who are redefining the future of neuromodulation across the nervous system. These perspectives will provide a roadmap for the next generation of neuromodulation therapies, where network-level understanding and adaptive technologies converge to deliver more precise, effective, and transformative patient care.

Presenters

  • Leigh R. Hochberg, MD, PhD

    Leigh R. Hochberg, MD, PhD

    L. Herbert Ballou University Professor of Engineering, Brown U.; Director, Center for Neurotechnology and Neurorecovery, Mass General; Assoc. Director, Center for Neurorestoration and Neurotechnology, VA Providence

    Massachusetts General Hosp, Brown University, VA Providence, Harvard Med School · Boston, Massachusetts

    Leigh R. Hochberg, MD, PhD is a neurointensivist and vascular neurologist, and the Cote Family TGS Endowed Chair in Neurotechnology at Mass General Brigham, and Senior Lecturer on Neurology at Harvard Medical School; the L. Herbert Ballou University Professor of Engineering and Professor of Brain Science at Brown University; and Associate Director, VA RR&D Center for Neurorestoration and Neurotechnology in Providence. He also directs the MGB Center for Neurotechnology and Neurorecovery, and is the IDE Sponsor-Investigator and PI of the BrainGate clinical trials, conducted by a consortium of scientists and clinicians at Brown, Emory, MGH, VA Providence Healthcare, Stanford, Baylor College of Medicine, and UC-Davis.